A Study of Nilotinib Versus Imatinib in GIST Patients
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients
with unresectable or metastatic gastrointestinal stromal tumors (GIST).